Aptevo Therapeutics Inc.
Organization details
- Legal name
- Aptevo Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- APVO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001671584
- EIN
- 81-1567056
Board of directors
-
Barbara Lopez Kunz · DirectorSince 2023
-
Daniel Abdun-Nabi · DirectorSince 2023
-
Grady Grant III · DirectorSince 2023
-
Jeffrey G. Lamothe · Director · President and CEOSince 2026
-
John Niederhuber · DirectorSince 2023
-
Marvin L. White · Director · Executive ChairSince 2023
-
Zsolt Harsanyi · DirectorSince 2023
Chief executives
Director election results
Annual meeting of August 21, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
90.0%
-
92.6%
Board connections
2 of this board's directors also sit on 1 other board. 1 is in the same sector.
-
Emergent BioSolutions Inc. Same sectorvia Marvin L. White and Zsolt Harsanyi
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 6, 2026 | Daniel Abdun-Nabi Director | Option exercise | +400 | — | — |
| Aug 6, 2026 | John Niederhuber Director | Option exercise | +400 | — | — |
| Aug 6, 2026 | Barbara Lopez Kunz Director | Option exercise | +400 | — | — |
| Aug 6, 2026 | Grady Grant III Director | Option exercise | +400 | — | — |
| Aug 6, 2026 | Huebner Dirk Officer (SVP, CMO) | Option exercise | +638 | — | — |
| Aug 6, 2026 | Kwon SoYoung Officer (SVP, GC, BD & Corp Affairs) | Option exercise | +638 | — | — |
| Aug 6, 2026 | Taylor Daphne Officer (SVP, CFO) | Option exercise | +638 | — | — |
| Aug 6, 2026 | Jeffrey G. Lamothe Director, Officer (President and CEO) | Option exercise | +961 | — | — |
| Aug 6, 2026 | Zsolt Harsanyi Director | Option exercise | +400 | — | — |
| Aug 6, 2026 | Marvin L. White Director, Officer (Executive Chair) | Option exercise | +1,666 | — | — |
| Aug 6, 2026 | Huebner Dirk Officer (SVP, CMO) | Shares withheld for tax | −156 | $4.07 | $635 |
| Aug 6, 2026 | Marvin L. White Director, Officer (Executive Chair) | Shares withheld for tax | −406 | $4.07 | $1,652 |
| Jul 17, 2026 | Marvin L. White Director, Officer (Executive Chair) | Option exercise | +1 | — | — |
| Nov 10, 2025 | Grady Grant III Director | Open-market purchase | +13,513 | $1.49 | $20,134 |
| Jul 17, 2025 | Zsolt Harsanyi Director | Option exercise | +1 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Aptevo Therapeutics Inc.
Who is the CEO of Aptevo Therapeutics Inc.?
Marvin L. White is Aptevo Therapeutics Inc.'s President and CEO.
How many directors are on Aptevo Therapeutics Inc.'s board?
Aptevo Therapeutics Inc.'s board has 7 directors: Barbara Lopez Kunz, Daniel Abdun-Nabi, Grady Grant III, Jeffrey G. Lamothe, John Niederhuber, Marvin L. White and Zsolt Harsanyi.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="aptevo-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.